清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

泊马度胺 地塞米松 医学 多发性骨髓瘤 耐火材料(行星科学) 内科学 肿瘤科 来那度胺 生物 天体生物学
作者
Hang Quach,Gurdeep Parmar,Enrique M. Ocio,H. Miles Prince,Albert Oriol,Nobuhiro Tsukada,Kazutaka Sunami,Pierre Bories,Sumit Madan,Dorothée Sémiond,Disa Yu,Sandrine Macé,Florence Suzan,Philippe Moreau
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 4412-4414 被引量:8
标识
DOI:10.1182/blood-2022-166840
摘要

Introduction: Intravenous (IV) administration of isatuximab (Isa) in combination with pomalidomide and dexamethasone (Pd) is approved for patients (pts) with relapsed/refractory multiple myeloma (RRMM). Subcutaneous (SC) delivery allows for a shorter duration of administration (within several minutes) compared with the currently approved IV route, optimizing convenience of administration and healthcare resources and enhancing comfort and quality of life of patients (pts). Prior results of the Phase 1b study (NCT04045795) defined the recommended phase 2 dose (RP2D) of SC Isa at 1400 mg and showed comparable safety and efficacy for both IV and SC routes of Isa administration in combination with Pd, in pts with RRMM. The on-body delivery system (OBDS), a wearable bolus injector applied to the abdomen by a healthcare professional, administered SC Isa in the expansion cohort, demonstrating very good local tolerability with a short follow-up. Here, we present updated results of this phase 1b trial. Methods: This multicenter, open-label, Phase 1b study evaluated SC vs IV Isa + Pd in pts with RRMM and ≥2 prior lines of treatment (LOT). Pts were randomized to SC by infusion pump (IP)1000 mg and IV 10 mg/kg or to IP1400 mg and IV. SC Isa administration at the RP2D via OBDS was evaluated in an expansion cohort. Primary endpoints were safety and pharmacokinetics (PK). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS) and CD38 receptor occupancy. Results: A total of 56 pts were randomized and treated: 12 with Isa IV, 12 with Isa IP1000, 10 with Isa IP1400, and 22 with Isa OBDS. On May 28, 2022, 33% IV, 25% IP1000, 30% IP1400, and 59% of OBDS pts remained on treatment. The median follow-up was longer for IV (24 mo), IP1000 (29 mo), IP1400 (23 mo) cohorts than the OBDS (10 mo) cohort due to sequential accrual. At study entry, 67% of IV, 33% of IP1000, 60% of IP1400, and 50% of OBDS pts had International Staging System stage II-III disease, and ≥50% of pts in each cohort had received ≥3 prior LOT. 50% of IV patients were refractory to immunomodulatory drugs and proteasome inhibitors, as well as 66.7% of IP1000, 40% of IP1400 and 72.7% of OBDS cohorts, respectively. Treatment-related G3-4 treatment emergent adverse events (TEAE) occurred in 91.7% pts of the IP1000 cohort and approximately 80% in the IV, IP1400 and OBDS cohorts (Table 1). Serious treatment-related TEAEs occurred in 16.7% pts of the IV, 25% in the IP1000, 50% in the IP1400 and 13.6% in the OBDS cohort. Isa administration was well tolerated, with infrequent infusion reactions (IRs) (≤10% in each cohort, all G2), only at first administration, and none in the OBDS cohort. The median duration of OBDS injections was 10 min, and all injections were successfully completed with no interruption. There was good local tolerability: 5 (22.7%) pts experienced 7 injection site reactions, all G1, out of 404 administrations (1.73%), including 5 injection site erythemas, 1 injection site hemorrhage, and 1 injection site induration. Grade ≥3 laboratory neutropenia was observed in 83% of IV patients and ~90% of SC patients, OBDS and IP. Febrile neutropenia occurred in 1 (4.5%) patient in the IV, 2 (20%) pts in the IP1400 and 1 (4.5%) in the OBDS cohorts. Flat SC dosing resulted in variability in Isa PK exposure generally comparable to the body weight based IV dosing, supporting the choice of a flat SC dose. Grade ≥3 laboratory neutropenia, febrile neutropenia, and infections were consistent across weight ranges (<65 kg, 65-85 kg, >85 kg). Best overall responses, median PFS, and duration of follow-up are presented (Table 2). ORR in pts treated at the RP2D was 75.0%, and 66.7% in the IV and IP1000 cohorts. Due to data availability, results of minimal residual disease assessments will be presented at the conference. Conclusions: These updated results with longer follow-up of SC Isa administration via OBDS at the RP2D of 1400 mg showed a safety profile consistent with IV administration, with no IRs, excellent local tolerability and efficacy comparable to that observed in the phase 3 ICARIA study with IV Isa, in combination with Pd. Isa SC administration by OBDS is well tolerated, has a short duration of injection, and provides a convenient hands-free option with controlled delivery. Based on these results and OBDS performance, a non-inferiority phase 3 trial of Isa-SC with OBDS versus Isa-IV is ongoing (NCT05405166). Clinical trial information: NCT04045795. Funding: Sanofi. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
伶俐小懒猪完成签到,获得积分10
12秒前
16秒前
孝顺的怜寒完成签到,获得积分10
27秒前
2797924221完成签到,获得积分10
29秒前
36秒前
Autin完成签到,获得积分0
39秒前
42秒前
tuimao发布了新的文献求助10
43秒前
keyan完成签到,获得积分10
46秒前
zx586440的应助被科研通管家采纳,获得20
52秒前
清脆晓瑶完成签到,获得积分10
53秒前
缓慢不正完成签到,获得积分10
1分钟前
1分钟前
木头鱼完成签到,获得积分10
1分钟前
淡定的板栗完成签到,获得积分10
1分钟前
悲伤的小袁完成签到,获得积分10
1分钟前
1分钟前
1分钟前
淡然的紫伊完成签到,获得积分10
1分钟前
迷人的晓灵完成签到,获得积分10
1分钟前
1分钟前
shoemaker完成签到,获得积分10
1分钟前
6666发布了新的文献求助10
1分钟前
Lemenchichi完成签到,获得积分10
1分钟前
害羞的又菡完成签到,获得积分10
1分钟前
1分钟前
甜蜜寻琴完成签到,获得积分10
2分钟前
沙海沉戈完成签到,获得积分0
2分钟前
含蓄的新柔完成签到,获得积分10
2分钟前
2分钟前
龙龙发布了新的文献求助10
2分钟前
小如意完成签到 ,获得积分10
2分钟前
我是老大的应助被龙龙采纳,获得10
2分钟前
renbaobei完成签到 ,获得积分10
2分钟前
典雅的醉易完成签到,获得积分10
2分钟前
2分钟前
充电宝的应助被Wang采纳,获得10
3分钟前
灵巧怀曼完成签到,获得积分10
3分钟前
TingtingGZ发布了新的文献求助10
3分钟前
细腻绮完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173194
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780476
捐赠科研通 7767279
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682